Primary Objective: Proportion of physicians reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients.~Secondary Objectives:~Explore the use of informed consent in tumor genetic testing in endometrial cancer~Explore clinician confidence in utilizing tumor genetic testing to guide treatment decisions.~Explore the impact of recent publications regarding immunotherapy on the use of tumor genetic testing in endometrial cancer.
In order to formulate strategies to improve adherence to best practice guidelines, as well as utilization of novel therapies, investigators must understand current practice patterns surrounding tumor genetic testing in endometrial cancer. The aim is to survey a representative sample of gynecologic oncologists who belong to the society of gynecologic oncology, via an email survey, to better understand current practices surrounding tumor genetic testing as well as determine if there have been any changes to practice since the publication of recent trials on the use of immune-checkpoint inhibitors in endometrial cancer.